The FDA has placed a partial clinical hold on studies of multiple myeloma treatment Venclexta/Venclyxto (venetoclax) following a number of patient deaths in a late stage study.
AbbVie who are developing the drug with Roche said the hold should not affect any of the improved indications such as in chronic lymphocytic leukaemia (CLL) and acute myeloid leukaemia (AML).
The FDA made the decision after seeing data from the Phase 3 BELLINI trial in patients with relapsed and refractory multiple myeloma.
